Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,316 across all filing types
Latest filing 2026-05-18 Report Publication Anno…
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
Transcript of Earnings call recordings held on May 12, 2026
Report Publication Announcement Classification · 84% confidence The document is a brief cover letter to stock exchanges notifying them that the earnings call transcript for Q4 FY26 is enclosed and uploaded online. It does not contain the actual transcript, only an announcement that the report is available. Under the “menu vs meal” rule, this is a Report Publication Announcement (RPA), not the call transcript itself.
2026-05-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2026-05-18 English
FORM 6-K
Foreign Filer Report
2026-05-18 English
FORM 6-K
Foreign Filer Report
2026-05-18 English
Intimation of Analyst/Investor meet
Regulatory Filings Classification · 85% confidence The document is a formal intimation under Regulation 30 of SEBI LODR to stock exchanges, providing the schedule of analyst/institutional investor meetings. It does not contain financial statements or results, nor is it a presentation, vote result, or report itself. It is a routine regulatory disclosure for compliance with listing obligations, and thus best fits the catch-all “Regulatory Filings” category (RNS).
2026-05-16 English
Press Release
Regulatory Filings Classification · 88% confidence The document is a press release announcing Dr. Reddy’s Laboratories’ launch of its generic Semaglutide Injection in Canada, submitted under SEBI Regulation 30 to stock exchanges. It contains no financial statements, voting results, management or audit reports, or other specific report content. This is a general regulatory announcement/filing (miscellaneous disclosure) rather than a formal financial report or presentation. Therefore, it should be classified as a Regulatory Filings (RNS).
2026-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.